Efficacy of palonosetron (PAL) compared to other serotonin inhibitors (5-HT3R) in preventing chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately or highly emetogenic (MoHE) treatment: Systematic review and meta-analysis

Supportive Care in Cancer

Volumn 19, Issue 6, 2011, Pages 823-832

  Ayer Botrel, Tobias Engel ^a   Clark, Otávio Augusto C ^a   Clark, Luciana ^a   Paladini, Luciano ^a   Faleiros, Enéas ^a   Pegoretti, Bruna ^a  

^a NONE   (Brazil)

Author keywords

Chemotherapy; Meta analysis; Nausea; Palonosetron; Vomiting

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CARMUSTINE; CHLORMETHINE; CISPLATIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DACARBAZINE; DOLASETRON MESILATE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; GRANISETRON; IDARUBICIN; IFOSFAMIDE; IRINOTECAN; METHOTREXATE; MITOXANTRONE; ONDANSETRON; PALONOSETRON; SEROTONIN ANTAGONIST; ANTIEMETIC AGENT; GLUCOCORTICOID; ISOQUINOLINE DERIVATIVE; QUINUCLIDINE DERIVATIVE; SEROTONIN 3 ANTAGONIST;

CONSTIPATION; DIARRHEA; DIZZINESS; HEADACHE; HUMAN; META ANALYSIS; NAUSEA AND VOMITING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SINGLE DRUG DOSE; SYSTEMATIC REVIEW; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; NAUSEA; NEOPLASM; VOMITING;

ANTIEMETICS; ANTINEOPLASTIC AGENTS; GLUCOCORTICOIDS; HUMANS; ISOQUINOLINES; NAUSEA; NEOPLASMS; QUINUCLIDINES; SEROTONIN 5-HT3 RECEPTOR ANTAGONISTS; VOMITING;

EID: 80051609353     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-010-0908-8     Document Type: Review

References (56)

1. Griffin AM, Butow PN, Coates AS, Childs AM, Ellis PM, Dunn SM et al (1996) On the receiving end. V: patient perceptions of the side effects of cancer chemotherapy in 1993. Ann Oncol 7 (2):189-195 (Pubitemid 26094884)
2. Navari RM, Reinhardt RR, Gralla RJ, Kris MG, Hesketh PJ, Khojasteh A et al (1999) Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. L-754, 030 Antie-metic Trials Group. N Engl J Med 340(3):190-195 (Pubitemid 29063215)
3. Almeida EP, Gutierrez MG, Adami NP (2004) [Monitoring and evaluation of side effects of chemotherapy in patients with colon cancer]. Rev Lat Am Enfermagem 12(5):760-766
4. Sharma R, Tobin P, Clarke SJ (2005) Management of chemotherapy-induced nausea, vomiting, oral mucositis, and diarrhoea. Lancet Oncol 6(2):93-102 (Pubitemid 40197703)
5. Gralla RJ (1991) Controlling emesis in patients receiving cancer chemotherapy. Recent Results Cancer Res 121:68-85
6. Hesketh PJ (1999) Defining the emetogenicity of cancer chemotherapy regimens: relevance to clinical practice. Oncologist 4 (3):191-196 (Pubitemid 29297482)
7. Koeller JM, Aapro MS, Gralla RJ, Grunberg SM, Hesketh PJ, Kris MG et al (2002) Antiemetic guidelines: creating a more practical treatment approach. Support Care Cancer 10(7):519-522 (Pubitemid 36061646)
8. Aapro MS (2007) Palonosetron as an anti-emetic and anti-nausea agent in oncology. Ther Clin Risk Manag 3(6):1009-1020
9. Navari RM (2006) Palonosetron: a second-generation 5-hydroxytryptamine receptor antagonist. Future Oncol 2(5):591-602 (Pubitemid 44575645)
10. Kris MG, Pisters KM, Hinkley L (1994) Delayed emesis following anticancer chemotherapy. Support Care Cancer 2 (5):297-300
11. Herrstedt J (2008) Antiemetics: an update and the MASCC guidelines applied in clinical practice. Nat Clin Pract Oncol 5 (1):32-43 (Pubitemid 351512427)
12. Navari RM, Province PS (2006) Emerging drugs for chemotherapy-induced emesis. Expert Opin Emerg Drugs 11 (1):137-151
13. Stoltz R, Cyong JC, Shah A, Parisi S (2004) Pharmacokinetic and safety evaluation of palonosetron, a 5-hydroxytryptamine-3 receptor antagonist, in U.S. and Japanese healthy subjects. J Clin Pharmacol 44(5):520-531 (Pubitemid 38509721)
14. Gralla R, Lichinitser M, Van Der Vegt S, Sleeboom H, Mezger J, Peschel C et al (2003) Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol 14 (10):1570-1577 (Pubitemid 37304615)
15. Eisenberg P, Figueroa-Vadillo J, Zamora R, Charu V, Hajdenberg J, Cartmell A et al (2003) Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron. Cancer 98(11):2473-2482 (Pubitemid 37466663)
16. Di Maio M, Gallo C, Perrone F (2008) [Meta-analysis of phase III studies with palonosetron in the prevention of vomiting induced by moderately emetogenic chemotherapy]. Tumori 94(suppl 2):14-22 (Pubitemid 351838840)
17. Jordan K, Hinke A, Grothey A, Voigt W, Arnold D, Wolf HH et al (2007) A meta-analysis comparing the efficacy of four 5-HT3-receptor antagonists for acute chemotherapy-induced emesis. Support Care Cancer 15(9):1023-1033 (Pubitemid 47340963)
18. Kris MG, Hesketh PJ, Somerfield MR, Feyer P, Clark-Snow R, Koeller JM et al (2006) American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol 24(18):2932-2947 (Pubitemid 46630595)
19. Dickersin K, Scherer R, Lefebvre C (1994) Identifying relevant studies for systematic reviews. BMJ 309(6964):1286-1291 (Pubitemid 24340510)
20. Clarke M, Oxman AD (ed) (2000) Cochrane Reviewers Handbook 4.1.1 [updated December 2000] In: The Cochrane Library, Issue 4, 2000. Oxford, Update Software
21. Castro AA, Clark OA, Atallah AN (1999) Optimal search strategy for clinical trials in the Latin American and Caribbean Health Science Literature database (LILACS database): update. São Paulo Med J 117(3):138-139
22. Egger M, Smith GD, Altman D (2001) Systematic Reviews in Health Care. BMJ, London
23. Parmar MK, Torri V, Stewart L (1998) Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 17(24):2815-2834 (Pubitemid 28562978)
24. Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327(7414):557-560 (Pubitemid 37088507)
25. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7(3):177-188 (Pubitemid 17189972)
26. Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315 (7109):629-634 (Pubitemid 27387172)
27. McQuay HJ, Moore RA (1997) Using numerical results from systematic reviews in clinical practice. Ann Intern Med 126 (9):712-720 (Pubitemid 27184043)
28. Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF (1999) Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses. Lancet 354(9193):1896-1900
29. Boccia RV, Gonzalez EF, Pluzanska AG, Clerici G (ed) (2008) Palonosetron (PALO), administered orally or intravenously (IV), plus dexamethasone for preventi. J Clin Oncol 26: (May 20 suppl; abstr 20608)
30. Brames MJ, Roth BJ, Dreicer R, Bubalo J, Nichols C, Cullen MT et al. (ed) (2006) Palonosetron (PALO) + dexamethasone (DEX) for prevention of chemotherapy (CT)-induced nausea and vomiting (CINV) in patients receiving multiple-day cisplatin CT for germ cell cancer. Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I Vol 24, No 18S (June 20 Supplement): 8607
31. Carreca I, Bellomo F, Bronte G, Burgio M, Piazza D, Rizzo S et al. (ed)(2007) Impact of the new 5-HT3 receptor antagonist palonosetron (P) in chemotherapy-induced nausea and vomiting (CINV) control in elderly advanced breast cancer (EABC) patients: comparison with the classic antiemetic agent ondansetron (O). Breast Cancer Symposium
32. Celio L, Denaro A, Canova S, Gevorgyan A, Bajetta E (2008) Clinical update on palonosetron in the management of chemotherapy-induced nausea and vomiting. Tumori 94(4):447-452
33. Giralt S, Mangan K, Maziarz R, Bubalo JS, Beveridge R, Hurd DD et al. (ed)(2008) Palonosetron (PALO) for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving high-dose melphalan prior to stem cell transplant (SCT). J Clin Oncol 26: (May 20 suppl; abstr 9617)
34. Grunberg SM, Burgt JAV, Berry S, Rubenstein EB, Berry D (ed) (2004) Prevention of delayed nausea and vomiting (D-CINV): Carryover effect analysis of pooled data from 2 phase III studies of palonosetron (PALO). Journal of Clinical Oncology, 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition) Vol 22, No 14 S (July 15 Supplement): 8051
35. Hunt TL, Gallagher SC, Cullen MT Jr, Shah AK (2005) Evaluation of safety and pharmacokinetics of consecutive multiple-day dosing of palonosetron in healthy subjects. J Clin Pharmacol 45(5):589-596 (Pubitemid 40562950)
36. Kadota R, Shen V, Messinger Y (ed) (2007) Safety, pharmacoki-netics, and efficacy of palonosetron in pediatric patients: A multicenter, stratified, double-blind, phase 3, randomized study. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I Vol 25, No 18 S (June 20 Supplement): 9570
37. Labianca R, Mandala M, Clerici M (2008) [Clinical role of palonosetron for patients receiving cisplatin-based chemotherapy]. Tumori 94(suppl 2):23-25 (Pubitemid 351838841)
38. Pradelli L, Eandi M (2008) [Palonosetron in the prevention of chemotherapy-induced nausea and vomiting (CINV) in Italy: pharmacologic, clinical and economic aspects]. Tumori 94(suppl 2):26-32 (Pubitemid 351838842)
39. Rojas C, Stathis M, Alt J, Rubenstein E, Cantoreggi S, Sebastiani S et al.(ed) (2007) Additional binding mechanism of palonosetron to the 5-HT3 receptor versus first generation 5-HT3 receptorantagonists. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I Vol 25, No 18S (June 20 Supplement): 19583
40. Rubenstein EB, Gralla RJ, Eisenberg P, Sleeboom, Vtoraya O, Macciocchi A et al. (ed)(2003) Palonosetron (PALO) compared with ondansetron (OND) or dolasetron (DOL) for Prevention of Acute & Delayed Chemotherapy-Induced Nausea and Vomiting (CINV): Combined Results of Two Phase III Trials. Proc Am Soc Clin Oncol 22: (abstr 2932).
41. Saito M, Aogi K, Sekine I, Yoshizawa H, Yanagita Y, Sakai H et al (2009) Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial. Lancet Oncol 10(2):115-124
42. Sekine I, Saito M, Aogi K, Yoshizawa H, Yanagita Y, Sakai H et al. (ed)(2008) Palonosetron (PALO) versus granisetron (GRAN), both combined with dexamethasone (DEX) in preventing chemotherapy-induced nausea and vomiting (CINV) associated with cisplatin-or anthracycline plus cyclophosphamide-based regimens: Results of a phase III trial in Japanese patients. J Clin Oncol 26: (May 20 suppl; abstr 20749).
43. Shah AK, Hunt TL, Gallagher SC, Cullen MT Jr (2005) Pharmacokinetics of palonosetron in combination with aprepitant in healthy volunteers. Curr Med Res Opin 21 (4):595-601 (Pubitemid 40676112)
44. Aapro MS, Grunberg SM, Manikhas GM, Olivares G, Suarez T, Tjulandin SA et al (2006) A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Ann Oncol 17(9):1441-1449 (Pubitemid 44400384)
45. Sepúlveda-Vildósola AC, Betanzos-Cabrera Y, Lastiri GG, Rivera-Marquez H, Villasis-Keever MA, Del Angel VW et al (2008) Palonosetron hydrochloride is an effective and safe option to prevent chemotherapy-induced nausea and vomiting in children. Arch Med Res 39(6):601-606 (Pubitemid 352033608)
46. Yu Z, Liu W, Wang L, Liang H, Huang Y, Si X et al (2009) The efficacy and safety of palonosetron compared with granisetron in preventing highly emetogenic chemotherapy-induced vomiting in the Chinese cancer patients: a phase II, multicenter, randomized, double-blind, parallel, comparative clinical trial. Support Care Cancer 17(1):99-102
47. National Cancer Institute. [October, 2009]; Available from: http://www.cancer.gov/cancertopics/pdq/supportivecare/nausea/Health Professional/page7
48. Massa E, Astara G, Madeddu C, Dessi M, Loi C, Lepori S et al (2009) Palonosetron plus dexamethasone effectively prevents acute and delayed chemotherapy-induced nausea and vomiting following highly or moderately emetogenic chemotherapy in pre-treated patients who have failed to respond to a previous antiemetic treatment: comparison between elderly and non-elderly patient response. Crit Rev Oncol Hematol 70(1):83-91
49. Ellebaek E, Herrstedt J (2008) Optimizing antiemetic therapy in multiple-day and multiple cycles of chemotherapy. Curr Opin Support Palliat Care 2(1):28-34
50. Aapro MS, Macciocchi A, Gridelli C (2005) Palonosetron improves prevention of chemotherapy-induced nausea and vomiting in elderly patients. J Support Oncol 3(5):369-374 (Pubitemid 41448263)
51. Hickok JT, Roscoe JA, Morrow GR, Bole CW, Zhao H, Hoelzer KL et al (2005) 5-Hydroxytryptamine-receptor antagonists versus prochlorperazine for control of delayed nausea caused by doxorubicin: a URCC CCOP randomised controlled trial. Lancet Oncol 6(10):765-772 (Pubitemid 41430717)
52. Siddiqui MA, Scott LJ (2004) Palonosetron. Drugs 64(10):1125-1132, discussion 33-4
53. Eisenberg P, MacKintosh FR, Ritch P, Cornett PA, Macciocchi A (2004) Efficacy, safety and pharmacokinetics of palonosetron in patients receiving highly emetogenic cisplatin-based chemotherapy: a dose-ranging clinical study. Ann Oncol 15(2):330-337 (Pubitemid 38262636)
54. Grote T, Cartmell A, Phillips N, Yanagihara R (2002) Efficacy of palonosetron (RS-25259) compared with dolasetron in preventing acute and delayed moderately emetogenic chemotherapy-induced nause and vomiting (CNIV): results of a phase III, randomized, controlled trial. Blood 100(11 (Pt 1)):497b
55. Bernardo G, Palumbo R, Frascaroli M, Bernardo A, Losurdo A, Poggi G et al. (ed)(2009) Palonosetron compared to ondansetron in the prevention of chemotherapy-induced nausea and vomiting: Activity, safety, and cost-effectiveness evaluation. J Clin Oncol 27: (suppl; abstr e20573)
56. Grous JJ, Riegel E, Gabrail N, Charu V, Arevalo-Araujo R, Yanagihara R et al. (ed)(2009) Phase III study of sustained release granisetron (APF530) compared to palonosetron for the prevention of chemotherapy-induced nausea and vomiting (CINV). J Clin Oncol 27:15s, (suppl; abstr 9627)